Chimeric Therapeutics Receives $1.62M Advance on FY26 R&D Tax Incentive
Key points
- Chimeric Therapeutics secures $1.62M advance from Endpoints Capital
- Funds will support Phase 1/2 clinical trial activities
- Repayment tied to FY26 Research and Development Tax Incentive
Full summary
Chimeric Therapeutics Ltd., an Australian cell therapy company, has secured a $1.62 million advance from Endpoints Capital under a funding facility secured against its anticipated FY26 Research and Development Tax Incentive (RDTI). This funding will support ongoing Phase 1/2 clinical trial activities and general working capital. The funding agreement provides Chimeric with early access to a portion of the anticipated FY26 RDTI, with interest charged at a commercial rate. Repayment is due by December 31, 2026, and can be repaid earlier subject to the terms of the facility.
Guidance
None
Outlook
None
Summary generated by a large language model. Please interpret with care.